Switch from protease inhibitor- to efavirenz-based antiretroviral therapy improves quality of life, treatment satisfaction and adherence with low rates of virological failure in virologically suppressed patients.
about
Health-related quality of life among military HIV patients on antiretroviral therapy.Deficient reporting and interpretation of non-inferiority randomized clinical trials in HIV patients: a systematic review.Health-related quality of life assessment after antiretroviral therapy: a review of the literature.Patient reported outcome instruments used in clinical trials of HIV-infected adults on NNRTI-based therapy: a 10-year review.Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials.Antiretroviral therapy for children in resource-limited settings: current regimens and the role of newer agents.Assessing adherence to antiretroviral therapy in randomized HIV clinical trials: a review of currently used methods.Review of the impact of NNRTI-based HIV treatment regimens on patient-reported disease burden.Adherence among rural HIV-infected patients in the deep south: a comparison between single-tablet and multi-tablet once-daily regimens.Moving forward with treatment options for HIV-infected children.Psychometric assessment of health-related quality of life and symptom experience in HIV patients treated with antiretroviral therapy.Impact on health-related quality of life of a switch from enfuvirtide to raltegravir among multidrug-resistant HIV-1-infected patients: a randomized open-label trial (EASIER-ANRS 138).Lower health-related quality of life predicts all-cause hospitalization among HIV-infected individuals.Cost-effectiveness of once-daily versus twice-daily regimens in the treatment of HIV infection in sub-Saharan Africa: a probabilistic decision model
P2860
Q33773075-4738EB66-3FEB-4E2F-A1DB-0A76F92277C9Q34713094-B6ECD90D-63AA-4DA0-87CF-942499FD1EFFQ35664740-A8BC27E1-3D9F-4BA6-86E4-23B059098376Q37366279-DF7BA82A-6673-4D16-B9A5-6296C24F2159Q37696578-427B36A3-C17C-4A5E-94BC-DA39A7E31795Q37925813-7A0BAC60-4119-4945-B5F3-491EAACF9FF2Q38086335-589818CA-2356-447D-B8B1-B9E85BB33DC5Q38151171-D57877E7-1C83-4756-98B6-2A8043A3CEFEQ38261526-ABD97932-56DA-449B-AACB-5EF7290161BAQ40063042-3ABB0DE9-3217-48DF-9B41-C48B68177ED6Q41613534-1D411427-1C83-4D21-8E4E-2A6622026628Q42787157-399172AA-2024-41E4-AB16-C7908F48F240Q54989234-AD10B98D-564A-4DBE-AA9E-181BE3AD5A2CQ57990836-55B6E314-8F12-45D0-AC2E-36162A45C54B
P2860
Switch from protease inhibitor- to efavirenz-based antiretroviral therapy improves quality of life, treatment satisfaction and adherence with low rates of virological failure in virologically suppressed patients.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Switch from protease inhibitor ...... logically suppressed patients.
@en
Switch from protease inhibitor ...... logically suppressed patients.
@nl
type
label
Switch from protease inhibitor ...... logically suppressed patients.
@en
Switch from protease inhibitor ...... logically suppressed patients.
@nl
prefLabel
Switch from protease inhibitor ...... logically suppressed patients.
@en
Switch from protease inhibitor ...... logically suppressed patients.
@nl
P2093
P2860
P356
P1476
Switch from protease inhibitor ...... logically suppressed patients.
@en
P2093
P2860
P304
P356
10.1258/IJSA.2009.008487
P577
2010-03-01T00:00:00Z